EPSILOGEN LTD
Get an alert when EPSILOGEN LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£7.8M
-12.6% vs 2023
Net assets
£10M
+48% vs 2023
Employees
21
+40% vs 2023
Profit before tax
-£13M
-3.6% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | — | — | — | |
| Operating profit | -£12,365,682 | -£12,587,150 | -1.8% | |
| Profit before tax | -£12,135,966 | -£12,575,668 | -3.6% | |
| Net profit | -£10,090,031 | -£10,103,663 | -0.1% | |
| Cash | £8,881,189 | £7,765,228 | -12.6% | |
| Total assets less current liabilities | — | — | — | |
| Net assets | £6,915,316 | £10,231,394 | +48% | |
| Equity | £6,915,316 | £10,231,394 | +48% | |
| Average employees | 15 | 21 | +40% | |
| Wages | £2,833,110 | £3,861,408 | +36.3% | |
| Directors' remuneration | £444,918 | £469,346 | +5.5% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Gearing (liabilities / total assets) | 54.7% | 30.6% | |
| Current ratio | 2.17x | 6.27x | |
| Interest cover | — | -76.31x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- EPSILOGEN LTD 2020-04-17 → present
- IGEM THERAPEUTICS LIMITED 2016-07-26 → 2020-04-17
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Significant events
- “On 19 March 2025, the Company acquired 100% of the issued shares of TigaTx, Inc. ("Tiga") whose principal activity is the development of immune-oncology therapeutics based on IgA antibodies. At completion of the transaction Tiga was merged into a wholly owned subsidiary of Epsilogen Ltd. The principal reason for this transaction was to acquire Tiga's IgA platform technology which is highly complementary with the Company's IgE platform.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 5 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BJORDAL, Marianne, Dr | Director | 2022-02-24 | Jan 1977 | Norwegian |
| FINAN, Peter Michael, Dr | Director | 2017-03-31 | Jul 1967 | British |
| GULATI, Sonia | Director | 2025-03-13 | Sep 1977 | American |
| SAFARIAN, Alek | Director | 2018-11-21 | Oct 1964 | Australian |
| UTENG, Marianne, Dr | Director | 2022-02-24 | Dec 1977 | Norwegian |
| WILSON, Tim Craig, Dr | Director | 2017-06-01 | Mar 1964 | British |
Show 5 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CHISWELL, David John | Director | 2019-04-24 | 2024-04-24 |
| COX, Vivienne Frances, Dr | Director | 2017-03-31 | 2022-02-24 |
| JOHNSON, Emma | Director | 2023-02-01 | 2025-12-10 |
| KARAGIANNIS, Sophia, Dr | Director | 2016-07-26 | 2017-03-31 |
| SIRINAKIS, Kyparissia Katie | Director | 2017-03-31 | 2018-11-21 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Epidarex Capital Iii Uk, Lp | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-03-31 | Ceased 2023-12-15 |
| Mr Alek Safarian | Individual | Shares 25–50%, Voting 25–50% | 2020-03-31 | Ceased 2022-02-24 |
| Alsa Uk Holdings Ltd | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-03-31 | Ceased 2020-09-28 |
| Epidarex Capital Ii, Lp | Corporate entity | Shares 25–50%, Voting 25–50% | 2017-06-26 | Ceased 2023-12-15 |
| Epidarex Capital Partners Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2017-03-31 | Ceased 2017-06-26 |
| Dr Sophia Karagiannis | Individual | Shares 25–50%, Voting 25–50% | 2016-07-26 | Ceased 2017-03-31 |
| Dr James Frederick Spicer | Individual | Shares 25–50%, Voting 25–50% | 2016-07-26 | Ceased 2017-03-31 |
| Vivienne Frances Cox | Individual | Shares 25–50%, Voting 25–50% | 2016-07-26 | Ceased 2017-03-31 |
Filing timeline
Last 20 of 103 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-04-02 MA Memorandum articles
- 2025-04-02 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-10 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-04 | AA | accounts | Accounts with accounts type full | |
| 2025-08-18 | SH01 | capital | Capital allotment shares | |
| 2025-07-25 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-06-20 | SH01 | capital | Capital allotment shares | |
| 2025-06-17 | CH01 | officers | Change person director company with change date | |
| 2025-04-09 | SH01 | capital | Capital allotment shares | |
| 2025-04-04 | SH01 | capital | Capital allotment shares | |
| 2025-04-03 | SH01 | capital | Capital allotment shares | |
| 2025-04-02 | MA | incorporation | Memorandum articles | |
| 2025-04-02 | RESOLUTIONS | resolution | Resolution | |
| 2025-03-27 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-10 | SH01 | capital | Capital allotment shares | |
| 2024-09-06 | SH01 | capital | Capital allotment shares | |
| 2024-09-05 | SH01 | capital | Capital allotment shares | |
| 2024-09-04 | SH01 | capital | Capital allotment shares | |
| 2024-08-12 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-08-09 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-08-09 | PSC08 | persons-with-significant-control | Notification of a person with significant control statement | |
| 2024-08-09 | PSC07 | persons-with-significant-control | Cessation of a person with significant control |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 9
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.